^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ITIL-168

    i
    Other names: ITIL-168
    Associations

    News

    Trials
    Company:
    Instil Bio
    Drug class:
    T-lymphocyte cell therapy
    Related drugs:
    Associations

    News

    Trials
    over1year
    DELTA-1: ITIL-168 in Advanced Melanoma (clinicaltrials.gov)
    P2, N=29, Terminated, Instil Bio | N=130 --> 29 | Trial completion date: Aug 2028 --> Feb 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2024 --> Feb 2023; Business Decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • ITIL-168
    almost2years
    DELTA-2: ITIL-168 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=0, Withdrawn, Instil Bio | N=27 --> 0 | Trial completion date: Aug 2028 --> Dec 2022 | Active, not recruiting --> Withdrawn | Trial primary completion date: Feb 2024 --> Dec 2022
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Keytruda (pembrolizumab) • cyclophosphamide • ITIL-168
    2years
    DELTA-1: ITIL-168 in Advanced Melanoma (clinicaltrials.gov)
    P2, N=130, Active, not recruiting, Instil Bio | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • ITIL-168
    2years
    DELTA-2: ITIL-168 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=27, Active, not recruiting, Instil Bio | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Keytruda (pembrolizumab) • cyclophosphamide • ITIL-168
    2years
    DELTA-1: ITIL-168 in Advanced Melanoma (clinicaltrials.gov)
    P2, N=130, Recruiting, Instil Bio | Trial completion date: Dec 2027 --> Aug 2028 | Trial primary completion date: Jun 2023 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • ITIL-168
    2years
    DELTA-2: ITIL-168 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=27, Recruiting, Instil Bio | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Keytruda (pembrolizumab) • cyclophosphamide • ITIL-168
    over2years
    DELTA-2: ITIL-168 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Instil Bio
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Keytruda (pembrolizumab) • cyclophosphamide • ITIL-168
    3years
    DELTA-1: ITIL-168 in Advanced Melanoma (clinicaltrials.gov)
    P2, N=130, Recruiting, Instil Bio
    Clinical • New P2 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    ITIL-168